Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Kidney Cancer Drugs Market $8.1 Billion by 2027

The global market for kidney cancer drugs to reach $8.1 billion by 2027, expanding at a CAGR of 6.3% over the forecast period, driven by increasing incidence of renal cell carcinoma, approval of new drugs and strong pipeline of potential molecules in phase II and III clinical trials.

  • The increase in the detection of asymptomatic and early cases attributed to advances and extensive use of imaging techniques. Early disease patients make up about two-thirds of all the cases diagnosed with renal cancer. 
Global Kidney Cancer Drugs Market

The most frequent type of kidney cancer is renal cell carcinoma (RCC), also called renal adenocarcinoma, or hypernephroma which represents over 90% of all renal malignancies. Renal cell carcinoma or kidney cancer drugs are often used as the first line of treatment against advanced kidney cancers.

  • RCC may be sporadic (~96%) or familial (4%) and is a heterogeneous group of disorders that are sub-classified into several distinct sub-types associated with distinct genetic abnormalities. Renal tumors are often detected incidentally during a computed tomography scan of the abdomen or chest that was ordered for unrelated symptoms. 

According to World Cancer Research Fund (WCRF), kidney cancer is the ninth most commonly occurring cancer in men and the 14th most commonly occurring cancer in women. There were over 400,000 new cases in 2018.


The global kidney cancer drugs market report estimates the market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for kidney cancer therapeutics segmented by product (brand) [Afinitor (everolimus), Avastin (bevacizumab), Inlyta (axitinib), Nexavar (sorafenib), Proleukin (aldesleukin), Sutent (sunitinib), Torisel (temsirolimus), Votrient (pazopanib)], pipeline analysis [AGS-003, Cabozantinib (XL184), Dovitinib (TK1258), Keytruda (Pembrolizumab), Opdivo (Nivolumab)), and geography.

  • The therapeutic options and management of renal cell carcinoma (RCC) are stage-dependent. Treatment options include active surveillance, ablation, nephron-sparing tumor excision, nephrectomy, and systemic treatment. Predictors of a poor prognosis include poor functional status and metastasis. In recent years new therapies have improved the prognosis for patients with metastatic disease
  • Several targeted agents are currently approved in the US and Europe for the treatment of metastatic renal cell carcinoma (mRCC), including tyrosine kinase inhibitors (TKIs) of the vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR) (sunitinib, axitinib, pazopanib and sorafenib, cabozantinib), anti-VEGF antibodies (bevacizumab in combination with INF-a) and inhibitors of the mammalian target of rapamycin (mTOR) pathway (temsirolimus and everolimus).

The global market for kidney cancer drugs research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • The incidence of kidney cancer varies widely among countries and among ethnic groups within countries. 
    • High incidence rates were seen in northern and eastern Europe, North America and Australia but the highest incidence rates were estimated in the Czech Republic.
    • Relatively low incidence rates were estimated in much of Africa and South-East Asia.
  • Kidney cancer is the seventh most common cancer in Europe, with more than 115,000 cases diagnosed every year and 49,000 deaths annually.
    • Incidence rates have been increasing in several European countries; however, the reasons for this are poorly understood, and the risk factors for kidney cancer are still poorly characterized.
      • Furthermore, the International Agency for Research on Cancer (IARC) projects a 22% increase by 2020, to about 413,000 cases.
  • The incidence and mortality of kidney cancer have steadily increased by 2%-3% per decade worldwide, and an increased risk of kidney cancer has been observed in many Asian countries. 
    • As the world’s population ages, and the prevalence of known risk factors such as obesity and hypertension increases, the burden of kidney cancer on individuals and society is predicted to increase significantly.

The global kidney cancer drugs market report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

Major competitors operating in the global market for kidney cancer treatment and included in this report are Bayer AG., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Merck & Co., Inc., Novartis AG., Pfizer, Inc., and Roche Holding AG (F. Hoffmann-La Roche AG)

  • Product (Brand)
    • Afinitor (Everolimus)
    • Avastin (Bevacizumab)
    • Inlyta (Axitinib)
    • Nexavar (Sorafenib)
    • Proleukin (Aldesleukin)
    • Sutent (Sunitinib)
    • Torisel (Temsirolimus)
    • Votrient (Pazopanib)
  • Pipeline Analysis (Phase III Candidates)
    • AGS-003
    • Cabozantinib (XL184)
    • Dovitinib (TK1258)
    • Keytruda (Pembrolizumab)
    • Opdivo (Nivolumab)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Bayer AG
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Roche Holding AG (F. Hoffmann-La Roche AG)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com